Stockreport

Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 ...

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
PDF the medication Orladeyo (berotralstat) for the prevention of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 and older in Brazil. Hereditar [Read more]